Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients
https://hal-amu.archives-ouvertes.fr/hal-02463220
Contributor : Isabelle Combe <>
Submitted on : Friday, January 31, 2020 - 5:58:23 PM Last modification on : Saturday, February 1, 2020 - 1:45:27 AM
A Awada, J Harding, Nuria Kotecki, P Aftimos, T. Decaens, et al.. Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients. 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Sep 2019, Barcelona, Spain. pp.286. ⟨hal-02463220⟩